CHICAGO, Sept. 16 IL-Advanced-Life-UBS
CHICAGO, Sept. 16 /PRNewswire-FirstCall/ -- Advanced Life Sciences
Holdings, Inc. (Nasdaq: ADLS) today announced that Dr. Michael Flavin,
Chairman and CEO will present at the 2008 UBS Global Life Sciences Conference
which will be held at the Grand Hyatt New York on Wednesday, September 24 at
4:30 p.m. EDT.
(Logo: http://www.newscom.com/cgi-bin/prnh/20080218/ALSLOGO)
A live webcast of the presentation will be accessible through the Investor
Relations page of the Advanced Life Sciences website at
http://www.advancedlifesciences.com. The presentation will be archived there
as well and available after the event for replay.
About Advanced Life Sciences
Advanced Life Sciences is a biopharmaceutical company engaged in the
discovery, development and commercialization of novel drugs in the therapeutic
areas of infection, cancer and respiratory diseases. The Company's lead
candidate, cethromycin, is a novel once-a-day oral antibiotic in late-stage
development for the treatment of respiratory tract infections including
community acquired pneumonia. For more information, please visit us on the web
at http://www.advancedlifesciences.com.
Any statements contained in this presentation that relate to future plans,
events or performance are forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. These forward-looking
statements are subject to a number of risks and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. These risks and uncertainties include, among
others, those relating to technology and product development, market
acceptance, government regulation and regulatory approval processes,
intellectual property rights and litigation, dependence on collaborative
relationships, ability to obtain financing, competitive products, industry
trends and other risks identified in Advanced Life Sciences' filings with the
Securities and Exchange Commission. Advanced Life Sciences undertakes no
obligation to update or alter these forward-looking statements as a result of
new information, future events or otherwise.
SOURCE Advanced Life Sciences Holdings, Inc.
